Discover 3,075 paid clinical trials in Houston, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Houston is home to world-renowned medical centers offering a variety of trials targeting conditions such as cancer, heart disease, diabetes, and Alzheimer’s. Healthy volunteers interested in paid research opportunities, as well as individuals in need of trials for specific conditions, can participate in these studies to access cutting-edge treatments and contribute to the development of innovative therapies.
Filter
2
Filter results
Results: 3,075
Active & Responsive
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
for
Premalignant Lesion
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06561087
Phase2, Recruiting
Active & Responsive
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: Houston TX, Oklahoma City OK, Nashville TN,
Sponsor: Phanes Therapeutics
Sex: All
Age: 18+
Code: NCT05431270
Phase1, Phase2, Recruiting
Active & Responsive
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Houston TX, Dallas TX, Oklahoma City OK, Charleston SC,
Sponsor: A2A Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT06136884
Phase1, Recruiting
Active & Responsive
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Houston TX, San Antonio TX, Nashville TN, St Louis MO,
Sponsor: Parabilis Medicines, Inc.
Sex: All
Age: 18+
Code: NCT05919264
Phase1, Phase2, Recruiting
Active & Responsive
Study of REM-422 in Patients With AML or Higher Risk MDS
for
Myelodysplastic Syndromes,
Location: Houston TX, Tampa FL, Duarte CA, New York NY, Boston MA
Sponsor: Remix Therapeutics
Sex: All
Age: 18+
Code: NCT06297941
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
for
Non-Small Cell Lung Cancer, NSCLC,
Location: Houston TX, Nashville TN, Charlotte NC,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT06043817
Phase1, Phase2, Recruiting
Active & Responsive
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
for
Metastatic Hepatocellular Carcinoma,
Location: Houston TX, Nashville TN, Zion IL, Goodyear AZ,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06427941
Phase1, Phase2, Recruiting
Active & Responsive
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
for
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms,
Location: Houston TX, Nashville TN, Urbana IL, Centerville OH,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05386108
Phase1, Phase2, Recruiting
Active & Responsive
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06066424
Phase1, Recruiting
Active & Responsive
What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
for
Breast Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 30+
Code: NCT04794816
Recruiting
Active & Responsive
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
for
Polycythemia Vera
Location: Houston TX, Sherman TX, Englewood CO, Roanoke VA,
Sponsor: Italfarmaco
Sex: All
Age: 18+
Code: NCT06093672
Phase3, Recruiting
Active & Responsive
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
for
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC),
Location: Houston TX, Fort Worth TX, Irving TX, Nashville TN,
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT07277413
Phase1, Recruiting
Active & Responsive
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
for
Advanced Solid Tumors, Genital Neoplasm, Female,
Location: Houston TX, San Antonio TX, Kansas City KS,
Sponsor: Marengo Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05592626
Phase1, Phase2, Recruiting
Active & Responsive
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
for
Advanced Solid Tumor
Location: Houston TX, Pittsburgh PA, Beverly Hills CA
Location: Houston TX, San Antonio TX, Fort Worth TX, Irving TX,
Sponsor: Pheast Therapeutics
Sex: All
Age: 18+
Code: NCT06840886
Phase1, Recruiting
Active & Responsive
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Location: Houston TX, Philadelphia PA, San Francisco CA
Sponsor: ITM Solucin GmbH
Sex: All
Age: 2 - 18
Code: NCT06441331
Phase1, Recruiting
Active & Responsive
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
for
Non-small Cell Lung Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07382726
Phase1, Recruiting
Active & Responsive
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
for
Phase 1b, Open Label, REC-617, RB1-Negative, Leiomyosarcoma